Cargando…
Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients
Breast cancer (BC) is not only a mass of malignant cells but also a systemic inflammatory disease. BC pro-tumorigenic inflammation has been shown to promote immune evasion and provoke BC progression. The NOD-like receptor (NLR) family pyrin domain-containing protein 3 (NLRP3) inflammasome is activat...
Autores principales: | Elgohary, Sawsan, Eissa, Reda A., El Tayebi, Hend M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531892/ https://www.ncbi.nlm.nih.gov/pubmed/37762557 http://dx.doi.org/10.3390/ijms241814254 |
Ejemplares similares
-
Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?
por: Elgohary, Sawsan, et al.
Publicado: (2021) -
A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach
por: Amer, Hoda T., et al.
Publicado: (2022) -
CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Ghallab, Alaa M., et al.
Publicado: (2022) -
Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis
por: Shide, Kotaro, et al.
Publicado: (2019) -
Backsplash Testbeam results for the SPD
por: Aguiló, E, et al.
Publicado: (2004)